Some 28 entities, including diagnostics makers Abbott Laboratories and Alere, submitted written comments on proposed amendments to Australia’s new regulatory framework for in vitro diagnostic devices. Posted online July 19 by Australia’s Therapeutic Goods Administration (TGA), the comments address amendments proposed by TGA on April 30, including proposals to give IVD manufacturers more time to comply with certain regulatory requirements; modify the conformity assessment procedure for class 4, high-risk laboratory-developed, or “in-house,” IVDs; introduce selective performance evaluation of class 4, high-risk IVDs submitted for design examination; and define genetic tests as medical devices.
The Australian agency said it will take all the comments into consideration as it prepares a regulation impact statement and moves toward full implementation of the country’s new IVD regulatory...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?